1. Home
  2. HLP vs ACET Comparison

HLP vs ACET Comparison

Compare HLP & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hongli Group Inc.

HLP

Hongli Group Inc.

HOLD

Current Price

$0.45

Market Cap

76.4M

Sector

Industrials

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$7.84

Market Cap

77.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HLP
ACET
Founded
2021
1947
Country
China
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.4M
77.3M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
HLP
ACET
Price
$0.45
$7.84
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$48.33
AVG Volume (30 Days)
419.5K
83.4K
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$51.63
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$0.46
52 Week High
$1.72
$9.05

Technical Indicators

Market Signals
Indicator
HLP
ACET
Relative Strength Index (RSI) 29.53 50.78
Support Level N/A $7.50
Resistance Level $0.72 $8.68
Average True Range (ATR) 0.15 0.54
MACD -0.04 -0.10
Stochastic Oscillator 13.51 43.65

Price Performance

Historical Comparison
HLP
ACET

About HLP Hongli Group Inc.

Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: